Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
481 articles by Ben Fidler
-
Merck gets a ‘surprise’ win for Keytruda in early lung cancer
Jan. 27, 2023 -
Veteran biotech leader George Scangos to step down as Vir CEO
Jan. 25, 2023 -
Three VCs launch Dimension, a new firm with plans to fuel biotech’s ‘digitization’
Jan. 25, 2023 -
Pliant shares jump on new data for lung disease drug
Jan. 23, 2023 -
With reverse merger, Elicio becomes latest biotech to bypass an IPO
Jan. 17, 2023 -
Al Sandrock on his short retirement and taking on a biotech turnaround project
Jan. 17, 2023 -
JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor
Jan. 11, 2023 -
JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies
Jan. 10, 2023 -
5 FDA decisions to watch in the first quarter
Jan. 9, 2023 -
Europe broadens Lynparza use as FDA ups scrutiny of PARP drugs
Dec. 21, 2022 -
Nimbus CEO Jeb Keiper on negotiating a $4B deal and building an unorthodox biotech startup
Dec. 16, 2022 -
Takeda to pay $4B for Nimbus’ TYK2 drug
Dec. 13, 2022 -
At ASH, Regeneron plays catch-up with its next cancer drugs
Dec. 12, 2022 -
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
Dec. 12, 2022 -
Pharvaris, pushing through trial pause, sees shares surge with new study results
Dec. 9, 2022 -
Relmada sinks further as depression drug fails second large trial
Dec. 8, 2022 -
Biotech veteran Jeff Jonas on leaving Sage, guiding new biotechs and his ‘personal odyssey’
Dec. 6, 2022 -
With new data, Nkarta builds case for ‘natural killer’ cell therapy
Dec. 5, 2022 -
FDA lifts pause on Beam plans to test base editing cancer therapy
Dec. 2, 2022 -
AstraZeneca reveals its cell therapy ambitions with deal for startup
Nov. 29, 2022 -
Biomolecular condensates: tiny droplets with big potential
Nov. 29, 2022 -
Trial failures end latest hope for Roche’s Alzheimer’s drug
Nov. 14, 2022 -
Ionis teams with Metagenomi and dives into gene editing
Nov. 14, 2022 -
Seagen picks Novartis, Flagship veteran Epstein as new CEO
Nov. 10, 2022 -
Biogen names former Sanofi head Viehbacher to replace Vounatsos as CEO
Nov. 10, 2022